Sweden: Sobi strengthens haematology franchise with acquisition of CTI for US$1.7bn

Swedish Orphan Biovitrum (Sobi), a specialised international biopharmaceutical company, is to acquire CTI BioPharma Corp, a biopharmaceutical company focused on blood related cancers and rare diseases, by means of a tender offer. The acquisition complements and further strengthens Sobi’s haematology franchise by adding VONJO, a differentiated product in the treatment of myelofibrosis, specifically addressing patients…

You must be a HMI Subscriber to view this content.

Subscribe Now »